Analysts say that all the attention being paid to the healthy effects of resveratrol should boost Sirtris' efforts to push through an IPO it hopes will raise up to $60 million. Sirtris is focused on advancing sirtuin drugs to treat metabolic disorders like Type 2 diabetes and other age and diet-related diseases. But with only one drug in an early-stage trial, Cambridge, MA-based Sirtris is heading for the market at a much earlier stage than most biotechs would contemplate these days.
- here's the AP report on the Sirtris IPO